A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

Summary

This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 injection in the treatment of patients with moderate to severe atopic dermatitis.

Timeline

Start

2024-04-30

Primary completion

2025-01-30

Completion

2026-01-30

Outcome

Met primary endpoint

release “曼多奇单抗（研发代号：AK120），在治疗中重度特应性皮炎（AD）的关键注册性Ⅲ期临床研究中取得阳性结果，研究的主要终点、关键次要终点及其他预设的多项次要终点全部成功” akesobio.com ↗

Drugs

Indications